To wrap up, we have shown for the first time that Arborinine showed inhibitory effect on ccRCC via KDM1A/UBE2O signaling, and a detailed regulatory mechanism warrants further investigation. This evidence concerns the gene UBE2O and nonpapillary renal cell carcinoma.